Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 20/20 | 0.71 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30615099 | 1.00 | USP1 (0.71) | USP1WDR48 | |
| SCHEMBL30782775 | 0.93 | USP1 (0.69) | USP1WDR48 | |
| SCHEMBL27088205 | 0.93 | USP1 (0.69) | USP1WDR48 | |
| SCHEMBL30033996 | 0.93 | USP1 (0.69) | USP1WDR48 | |
| SCHEMBL29296701 | 0.90 | USP1 (0.66) | USP1WDR48 | |
| SCHEMBL30782774 | 0.90 | USP1 (0.73) | USP1WDR48 | |
| SCHEMBL30878418 | 0.90 | USP1 (0.67) | USP1WDR48 | |
| SCHEMBL30782770 | 0.89 | USP1 (0.60) | USP1WDR48 | |
| SCHEMBL30696482 | 0.88 | USP1 (0.71) | USP1WDR48 | |
| SCHEMBL27174428 | 0.88 | USP1 (0.71) | USP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | USP1 1/4885WDR48 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.